Evaluate Vantage Homepage
Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Pepgen aims to overtake Sarepta
Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.
Big pharma’s key fourth-quarter data
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
Medtech
Ember burns bright for Angle
A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.
TCT 2022 – Otsuka’s renal denervation system shines
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
Company Events
FDA scrutiny now hits Parp inhibitors
A November adcom could decide whether Zejula will lose yet more ground to Lynparza.
Fourth-quarter data for the little guys
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Go or no go? GSK takes its turn with a novel anaemia class
Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.
Interviews
Pepgen aims to overtake Sarepta
Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.
T3D puts a bet on Alzheibetes
An unusual update at last month’s AAIC meeting puts the focus on a phase 2 readout next year, but time might be running out.
Novo’s cardiovascular and rare disease charge continues
Before the Forma deal Novo brought in assets via Corvidia, Prothena and Heartseed. Some have progressed faster than others.